Minimization of steroids in kidney transplantation

Transplant International

Volumn 22, Issue 1, 2009, Pages 38-48

  Matas, Arthur J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Kidney transplant; Steroid minimization

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE RECEPTOR ANTAGONIST; DACLIZUMAB; EVEROLIMUS; INTERLEUKIN 2 RECEPTOR INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; AVASCULAR NECROSIS; BLOOD GROUP ABO INCOMPATIBILITY; BODY MASS; CATARACT; CHOLESTEROL BLOOD LEVEL; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC GRAFT REJECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; FRACTURE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; NEGRO; NEOPLASM; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STEROID THERAPY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTIBODIES, MONOCLONAL; CHILD; CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION; PREDNISONE; RECURRENCE; STEROIDS; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 57349185160     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2008.00728.x     Document Type: Review

References (88)

1. Citterio F. Steroid side effects and their impact on transplantation outcome. Transplantation 2001 72 : S75.
2. Vanrenterghem YF, Claes K, Montagnino G, et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation 2008 85 : 209.
3. Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999 33 : 829.
4. Schweizer RT, Rovelli M, Palmeri D, Vossler E, Hull D, Bartus S. Noncompliance in organ transplant recipients. Transplantation 1990 49 : 374.
5. Nevins TE, Kruse L, Skeans MA, Thomas W. The natural history of azathioprine compliance after renal transplantation. Kidney Int 2001 60 : 1565.
6. Prasad GV, Nash MM, McFarlane PA, Zaltzman JS. Renal transplant recipient attitudes toward steroid use and steroid withdrawal. Clin Transplant 2003 17 : 135.
7. Montagnino G, Tarantino A, Maccario M, Elli A, Cesana B, Ponticelli C. Long-term results with cyclosporine monotherapy in renal transplant patients: a multivariate analysis of risk factors. Am J Kidney Dis 2000 35 : 1135.
8. Parrott NR, Hammad AQ, Watson CJE, Lodge JPA, Andrews CD. Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine A monotherapy in renal transplant recipients. Transplantation 2005 79 : 344.
9. Hricik DE, O'Toole MA, Schulak JA, Herson J. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993 4 : 1300.
10. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. Am Soc Nephrol 2000 11 : 1910.
11. Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 1992 147 : 645.
12. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993 55 : 752.
13. Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999 68 : 18650.
14. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000 70 : 1352.
15. Smak Gregoor PJH, De Sévaux RGL, Ligtenberg G, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002 13 : 1365.
16. Boletis JN, Konstadinidou I, Chelioti H, et al. Successful withdrawal of steroid after renal transplantation. Transplant Proc 2001 33 : 1231.
17. Squifflet JP, Vanrenterghem Y, van Hooff JP, Salmela K, Rogitti P the European Tacrolimus/MMF Transplantation Study Group. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. Transplant Proc 2002 34 : 1584.
18. Solá E, Alférez MJ, Cabello M, et al. Low-dose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil. Transplant Proc 2002 34 : 1689.
19. Pascual J, Quereda C, Zamora J, Hernández D Spanish Group for Evidence-Based Medicine in Renal Transplantation. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 2004 78 : 1548.
20. Pascual J, Quereda C, Zamora J, Hernández D Spanish Group for Evidence-Based Medicine in Renal Transplantation. Updated metaanalysis of steroid withdrawal in renal transplant patients on calcineurin inhibitor and mycophenolate mofetil. Transplant Proc 2005 37 : 3746.
21. Pascual J, van Hooff JP, Salmela K, Lang P, Rigotti P, Budde K. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation 2006 82 : 55.
22. Opelz G, Döhler B, Laux G, for the Collaborative Transplant Study. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 2005 5 : 720.
23. Pelletier RP, Akin B, Ferguson RM. Prospective, randomized trial of steroid withdrawal in kidney recipients treated with mycophenolate mofetil and cyclosporine. Clin Transplant 2006 20 : 10.
24. Wlodarczyk Z, Walaszewski J, Perner F, et al. Steroid withdrawal at 3 months after kidney transplantation: a comparison of two tacrolimus-based regimens. Transplant Int 2005 18 : 157.
25. Buchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007 7 : 2522.
26. Mahalati K, Kahan BD. A pilot study of steroid withdrawal from kidney transplant recipients on sirolimus-cyclosporine a combination therapy. Transplant Proc 2001 33 : 3232.
27. Citterio F, Sparacino V, Altieri P, et al. Addition of sirolimus to cyclosporine in long-term kidney transplant recipients to withdraw steroid. Transplant Proc 2005 37 : 827.
28. Hricik DE, Knauss TC, Bodziak KA, et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2003 76 : 938.
29. Hricik DE, Augustine JJ, Knauss TC, et al. Long-term graft outcomes after steroid withdrawal in AA kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2007 83 : 277.
30. Birkeland SA. Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. Transplantation 2002 73 : 1527.
31. Birkeland SA. Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients. Transplantation 2001 71 : 1089.
32. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003 3 : 306.
33. ter Meulen CG, van Riemsdijk I, Hené RJ, et al. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. Am J Transplant 2004 4 : 803.
34. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005 79 : 807.
35. Vitko S, Klinger M, Salmela K. Two corticosteroid-free regimens - tacrolimus monotherapy after basiliximab administration and tacrolimus/ mycophenolate mofetil - in comparison with a standard triple regimen in renal transplantation: results of the Atlas Study. Transplantation 2005 80 : 1734.
36. Woodle ES, for the TRIMS Study Group. A randomized, prospective, multicenter comparative study evaluating a Thymoglobulin-based early corticosteroid cessation regimen in renal transplantation (TRIMS). Am J Transplant 2006 6 : 5294.
37. Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008 8 : 307.
38. Laftavi MR, Stephan R, Stefanick B, et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 2005 137 : 364.
39. Woodle ES, Astellas Steroid Withdrawal Study Group. A randomized double blind, placebo-controlled trial of early corticosteroid cessation versus chronic corticosteroids: three-year results. Am J Transplant 2006 6 : S177.
40. Montagnino G, Sandrini S, Iorio B, et al. A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. Nephrol Dial Transplant 2008 23 : 707.
41. Kumar MS, Heifets M, Moritz MJ, et al. Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. Transplantation 2006 81 : 832.
42. Kumar MSA, Heifets M, Fyfe B, et al. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation 2005 80 : 807.
43. Boots JM, Christiaans MHL, Van Duijnhoven EM, van Suylen RJ, van Hooff JP. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. Transplantation 2002 74 : 1703.
44. Cole E, Landsberg D, David R, et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001 72 : 845.
45. Rajab A, Pelletier RP, Henry ML, et al. Excellent clinical outcomes in primary kidney transplant recipients treated with steroid-free maintenance immunosuppression. Clin Transplant 2006 20 : 537.
46. Woodle ES, Vincenti F, Lorber MI, et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under Simulect, tacrolimus and sirolimus. Am J Transplant 2005 5 : 157.
47. Kato Y, Tojimbara T, Iwadoh K, et al. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients. Int Immunopharmacol 2006 6 : 1984.
48. Jaber JJ, Feustel PJ, Elbahloul O, et al. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol. Clin Transplant 2007 21 : 101.
49. Matas AJ, Ramcharan T, Paraskevas S, et al. Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant 2001 1 : 278.
50. Humar A, Kandaswamy R, Payne W, et al. 6 years of prednisone-free maintenance immunosuppression. Am J Transplant 2006 6 : S482.
51. Matas AJ, Kandaswamy R, Humar A, et al. Long-term immunosuppression, without maintenance prednisone, after kidney transplantation. Ann Surg 2004 240 : 510.
52. Gallon LG, Winoto J, Leventhal JR, et al. Effect of prednisone versus no prednisone as part of maintenance immunosuppression on long-term renal transplant function. Clin J Am Soc Nephrol 2006 1 : 1029.
53. van den Ham EC, Kooman JP, Christiaans MH, Nieman FH, van Hooff JP. Weight changes after renal transplantation: a comparison between patients on 5-mg maintenance steroid therapy and those on steroid-free immunosuppressive therapy. Transplant Int 2003 16 : 300.
54. Mataunami C, Hilton AF, Dyer JA, Rumbach OW, Hardie IR. Ocular complications in renal transplant patients. Aust N Z J Ophthalmol 1994 22 : 53.
55. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis J, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991 325 : 544.
56. Wolpaw T, Deal CL, Fleming-Brooks S, Bartucci MR, Schulak JA, Hricik DE. Factors influencing vertebral bone density after renal transplantation. Transplantation 1994 58 : 1186.
57. Lo Cascio V, Bonucci E, Imbimbo B, et al. Bone loss after glucocorticoid therapy. Calcif Tissue Int 1984 36 : 435.
58. Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van't Hof MA, Lemmens JA. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993 119 : 963.
59. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000 39 : 1383.
60. Gluck OS, Murphy WA, Hahn TJ, Hahn B. Bone loss in adults receiving alternate-day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum 1981 24 : 892.
61. Ruegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1983 25 : 615.
62. Birkeland SA, Larsen KE, Rohr N. Pediatric renal transplantation without steroids. Pediatr Nephrol 1998 12 : 87.
63. Sarwal MM, Yorgin PD, Alexander S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001 72 : 13.
64. Sarwal MM, Vidhun JR, Alexander SR, et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003 76 : 1331.
65. Oberholzer J, John E, Lumpaopong A, et al. Early discontinuation of steroids is safe and effective in pediatric kidney transplant recipients. Pediatr Transplant 2005 9 : 456.
66. Chavers BM, Chang C, Gillingham KJ, Matas AJ. Successful pediatric kidney transplantation using a novel protocol of rapid discontinuation of prednisone. J Am Soc Nephrol (Abstr Issue) 2006 17 : 672A.
67. Haririan A, Sillix DH, Morawski K, et al. Short-term experience with early steroid withdrawal in African-American renal transplant recipients. Am J Transplant 2006 6 : 2396.
68. Boardman RE, Alloway RR, Alexander JW, et al. African-American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression. Am J Transplant 2005 5 : 356.
69. Anil Kumar MS, Moritz MJ, Saaed MI, et al. Avoidance of chronic steroid therapy in African American kidney transplant recipients monitored by surveillance biopsy: 1-year results. Am J Transplant 2005 5 : 1976.
70. Zeng X, El-Amm JM, Doshi MD, et al. Intermediate-term outcomes with early steroid withdrawal in African-American renal transplant recipients undergoing surveillance biopsy. Surgery 2007 142 : 538.
71. Anil Kumar MS, Khan S, Ranganna K, Malat G, Sustento-Reodica N, Meyers WC. Long-term outcome of early steroid withdrawal after kidney transplantation in African American recipients monitored by surveillance biopsy. Am J Transplant 2008 8 : 574.
72. Ibrahim H, Rogers T, Casingal V, et al. Graft loss from recurrent glomerulonephritis is not increased with a rapid steroid discontinuation protocol. Transplantation 2006 81 : 214.
73. Boardman R, Trofe J, Alloway R, et al. Early steroid withdrawal does not increase risk for recurrent focal segmental glomerulosclerosis. Transplant Proc 2006 37 : 817.
74. Kwajha K, Asolati M, Harmon JV, et al. Rapid discontinuation of prednisone in higher-risk kidney transplant recipients. Transplantation 2004 78 : 1397.
75. Alloway RR, Hanaway MJ, Trofe J, et al. A prospective, pilot study of early corticosteroid cessation in high-immunologic-risk patients: the Cincinnati experience. Transplant Proc 2005 37 : 802.
76. Cantarovich D, Giral-Classe M, Hourmant M, et al. Low incidence of kidney rejection after simultaneous kidney-pancreas transplantation after antithymocyte globulin induction and in the absence of corticosteroids: results of a prospective pilot study in 28 consecutive cases. Transplantation 2000 69 : 1505.
77. Kaufman DB, Leventhal JR, Koffron AJ, et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/ mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 2002 73 : 169.
78. Gallon LG, Winoto J, Chhabra D, et al. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 2007 83 : 1324.
79. Kaufman DB, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results. Am J Transplant 2006 6 : 331.
80. Rajab A, Pelletier RP, Ferguson RM, Elkhammas EA, Bumgardner GL, Henry ML. Steroid-free maintenance immunosuppression with Rapamune and low-dose Neoral in pancreas transplant recipients. Transplantation 2007 84 : 1131.
81. Cantarovitch D, Karam G, Hourmant M, et al. Steroid avoidance versus steroid withdrawal after simultaneous pancreas-kidney transplantation. Am J Transplant 2005 5 : 1332.
82. Kandaswamy R, Melancon JK, Dunn T, et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients - an interim analysis. Am J Transplant 2005 5 : 1529.
83. Gallon L, Perico N, Dimitrov BD, et al. Long-term renal allograft function on a tacrolimus-based, prednisone-free maintenance immunosuppression comparing sirolimus vs. MMF. Am J Transplant 2006 6 : 1617.
84. Humar A, Gillingham K, Kandaswamy R, Payne W, Matas A. Steroid avoidance regimens: a comparison of outcomes with maintenance steroids versus continued steroid avoidance in recipients having an acute rejection episode. Am J Transplant 2007 7 : 1948.
85. USRDS 2007. Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Transplantation. Am J Kid Dis 2008 51 : S155.
86. Almawi WY, Melemedjian OK, Rieder MJ. An alternate mechanism of glucocorticoid anti-proliferative effect: promotion of a Th2 cytokine-secreting profile. Clin Transplant 1999 13 : 365.
87. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002 62 : 1060.
88. van Duijnhoven EM, Boots JM, Christiaans MH, Stolk LM, Undre NA, van Hooff JP. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 2003 16 : 721.